Advanced in Leukemia

Dr. Michelle L. Hermiston

Pediatric Hematology Oncology
505 Parnassus Ave, 
San Francisco, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Leukemia
505 Parnassus Ave, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michelle Hermiston is a Pediatric Hematologist Oncology provider in San Francisco, California. Dr. Hermiston is rated as an Advanced provider by MediFind in the treatment of Leukemia. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Hemophagocytic Lymphohistiocytosis, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 87 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 39 articles and participated in 5 clinical trials in the study of Leukemia.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

505 Parnassus Ave, San Francisco, CA 94143

Additional Areas of Focus

Dr. Hermiston has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Enrollment Status: Recruiting
Publish Date: May 25, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Prednisone, Vinblastine, Mercaptopurine, Indomethacin, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, Intravenous immunoglobulin
Study Phase: Phase 2/Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Biological
Study Drug: CTL019
Study Phase: Phase 2
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drugs: Ruxolitinib, Dexamethasone, Etoposide
Study Phase: Phase 1/Phase 2
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2024
Intervention Type: Biological
Study Drugs: Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab
Study Phase: Phase 2
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: June 20, 2024
Intervention Type: Drug, Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
Enrollment Status: Completed
Publish Date: April 30, 2024
Intervention Type: Drug
Study Drugs: Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
Study Phase: Phase 2
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia
A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML
Enrollment Status: Completed
Publish Date: June 24, 2022
Intervention Type: Drug
Study Drugs: Decitabine, Vorinostat, Filgrastim, Fludarabine, Cytarabine
Study Phase: Phase 1
View 11 Less Clinical Trials

87 Total Publications

Emapalumab treatment in rheumatologic disease-associated hemophagocytic lymphohistiocytosis: a plain language summary.
Emapalumab treatment in rheumatologic disease-associated hemophagocytic lymphohistiocytosis: a plain language summary.
Journal: Immunotherapy
Published: June 18, 2025
Similar Doctors
Elite in Leukemia
Dr. Mignon L. Loh
Pediatric Hematology Oncology
Elite in Leukemia
Dr. Mignon L. Loh
Pediatric Hematology Oncology
505 Parnassus Ave # M-647, 
San Francisco, CA 
 (0.1 miles away)
415-476-3831
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mignon Loh is a Pediatric Hematologist Oncology provider in San Francisco, California. Dr. Loh is rated as a Distinguished provider by MediFind in the treatment of Leukemia. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Juvenile Myelomonocytic Leukemia (JMML), Bone Marrow Aspiration, and Bone Marrow Transplant.

Distinguished in Leukemia
Dr. Norman J. Lacayo
Pediatric Hematology Oncology
Distinguished in Leukemia
Dr. Norman J. Lacayo
Pediatric Hematology Oncology
725 Welch Rd, 
Palo Alto, CA 
 (27.4 miles away)
650-497-8000
Languages Spoken:
English
See accepted insurances

Norman Lacayo is a Pediatric Hematologist Oncology provider in Palo Alto, California. Dr. Lacayo is rated as a Distinguished provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Childhood Acute Myeloid Leukemia, Neuroblastoma, and Bone Marrow Aspiration.

Distinguished in Leukemia
Dr. Liora M. Schultz
Pediatric Hematology Oncology
Distinguished in Leukemia
Dr. Liora M. Schultz
Pediatric Hematology Oncology

Lpch Medical Group Div Of Lucile

725 Welch Rd, 
Palo Alto, CA 
 (27.4 miles away)
650-498-7200
Languages Spoken:
English
See accepted insurances

Liora Schultz is a Pediatric Hematologist Oncology provider in Palo Alto, California. Dr. Schultz is rated as a Distinguished provider by MediFind in the treatment of Leukemia. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hermiston's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile